|Slideshows|March 15, 2018

A New Tool for Springtime Mania

An environmental approach to mania makes it possible to “slow down the sun” and modulate the destabilizing effects of spring sunlight. More in this report.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Lamotrigine: An Update on Its Role in Bipolar Disorder

ByDavid N. Osser, MD

November 14th 2025

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

ByLeah Kuntz

October 23rd 2025

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

ByLeah Kuntz

October 16th 2025

The Use of Aripiprazole for Bipolar Disorder

ByDavid N. Osser, MD

October 15th 2025

An Update on Hyperthymic Temperament

ByDavid N. Osser, MD

September 18th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

A New Tool for Springtime Mania

Newsletter

Related Content

Lamotrigine: An Update on Its Role in Bipolar Disorder

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

The Use of Aripiprazole for Bipolar Disorder

An Update on Hyperthymic Temperament

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA